// App-Quantinova.ai

3847 : Creating the tumor microenvironment for effective immunotherapy: Antitumor activity of intratumoral IMO-2125, a TLR9 agonist is further enhanced by inhibition of indoleamine-pyrrole 2,3-dioxygenase (IDO)

Researchers

Presenter

  • Daqing Wang

Principal Investigators

  • Wayne Jiang

  • Bhagat Lakshmi

  • Jillian DiMuzio

  • Fugang Zhu

  • Sudhir Agrawal

Medical Centers

  • ARIAD Pharmaceuticals, Inc., Cambridge, MA

Locations

  • United States

Companies

  • Idera Pharmaceutical

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • Indoleamine 2,3-dioxygenase 1

  • Interleukin 12

  • tumor-infiltrating lymphocytes

  • Type 1 T helper

Drug/Treatment

  • IMO-2125

  • IL-12

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved